Comparing the current results to its competitors, Celularity Inc reported Revenue decrease in the 4 quarter 2025 year on year by -77.37 %, despite the revenue increase by the most of its competitors of 8.14 %, recorded in the same quarter.
Celularity Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes biopharmaceutical companies, academic institutions, governmental agencies, and research institutions developing novel and cellular therapies. Competitors in allogeneic natural killer (NK) cellular therapies include Fate Therapeutics Inc., Century Therapeutics, Inc., Nkarta, Inc., Artiva Biotherapeutics, Wugen, and Shoreline Biosciences. In the area of allogeneic mesenchymal lineage adult stem cell (MLASC) therapies, competitors include Mesoblast Limited and Longeveron. Additional cellular therapy competitors comprise Allogene Therapeutics, Inc., Atara Biotherapeutics, Inc., Adaptimmune Therapeutics PLC, Celyad S.A., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Gilead Sciences, Inc., Poseida Therapeutics, Inc., Precision Biosciences, Inc., Sangamo Therapeutics, Inc., Fate Therapeutics, Sana Biotechnology, Caribou Bio, and Artiva Biotherapeutics. Competitors in biomaterials include Mimedx Group, Inc., Organogenesis Holdings Inc., Skye Biologics Holdings LLC, Regenerative Labs, and Legacy Medical Consultants. The company also faces competition from non-cell-based therapies developed by small-cap biotechnology firms and large-cap pharmaceutical companies such as Amgen Inc., AstraZeneca plc, Bristol Myers Squibb Company, Incyte Corporation, Merck & Co., Inc., and F. Hoffmann-La Roche AG. Many competitors possess greater financial resources and expertise in research, development, clinical trials, manufacturing, and marketing. Future collaborations and mergers may lead to further consolidation of resources among fewer competitors.
January 4, 2024
Celularity, a leading biotechnology company specializing in allogeneic cell therapies and advanced biomaterial products, has recently entered into an exclusive strategic commercialization agreement with BioCellgraft. This agreement will see Celularity manufacturing advanced biomaterial products for BioCellgraft s distribution in the United States, specifically for dental and oral healthcare applications. This partnership holds significant promise for both companies and the overall advancement of oral healthcare.Facts and Assessments:1. Celularity s Exclusive U.S. Strategic Commercialization Agreement:The alliance between Celularity and BioCellgraft signifies a key milestone for Celularity s expansion into th...
Verastem Inc is a biopharmaceutical company that focuses on discovering and developing medicines to treat cancer by targeting the underlying biology of the disease. They employ a research-driven business model to identify novel therapeutic candidates, evaluate their potential through preclinical and clinical trials, and bring them to market with the goal of improving patient outcomes. Verastem emphasizes innovation, precision medicine, and strategic collaborations to advance their pipeline of cancer therapeutics.
Nkgen Biotech Inc is a biotechnology company that focuses on developing and commercializing innovative cell therapies for the treatment of various diseases. Their business model involves conducting extensive research to identify and isolate specific cells capable of addressing medical conditions, followed by developing manufacturing processes to produce these cells in large quantities. They aim to partner with healthcare providers and pharmaceutical companies to ensure the effective distribution and delivery of their therapies to patients in need.
Merus N V is a biotechnology company that operates using a differentiated and competitive business model. Their approach involves strategically targeting and developing bispecific antibodies to treat various types of cancer, leveraging their proprietary technologies and expertise in the field. By focusing on innovative research, efficient drug discovery, and partnerships, they aim to improve patient outcomes and drive growth in the oncology market.
Sources:
Celularity Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Celularity Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
